An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimer’s Disease Treatment?

Stefania Merighi1*, Tino Emanuele Poloni2, Lucia Pelloni1, Silvia Pasquini1, Katia Varani1, Fabrizio Vincenzi1, Pier Andrea Borea3 and Stefania Gessi1*

1Department of Translational Medicine and for Romagna, University of Ferrara, Ferrara, Italy, 2Department of Neurology and Neuropathology, Golgi-Cenci Foundation and ASP Golgi-Redaelli, Abbiategrasso, Italy, 3University of Ferrara, Ferrara, Italy

Keywords: A2A adenosine receptor, Alzheimer’s disease, biomarker, neuroinflammation, therapeutic target

INTRODUCTION

Neurocognitive Disorder due to Alzheimer’s Disease: A Brief Overview

According to DSM5, the term neurocognitive disorder (NCD) emphasizes that the cause of mental deficit lies in a pathology affecting neuronal circuits. The early clinical stages of NCD (mild-NCD/MCI) are characterized by functional preservation of everyday activities. Instead, if the disorder has a functional impact it is defined as major-NCD (dementia). On the other hand, the definition of the underlying pathology allows for the etiological classification of NCD (American Psychiatric Association, 2013; Sachdev et al., 2015). Based on the pathological deposition of proteins in brain tissue, NCD due to AD is characterized by a dual proteinopathy in which neurodegeneration is associated with the deposition of amyloid and phosphorylated TAU protein (pTAU). AD is the main age-related degenerative NCD progressively involving memory, complex attention, executive functions, language, and visual-perceptual functions. Personality and behavioural changes are also frequent further complicating the clinical course. On the other hand, due to the late involvement of the movement centers, motor function is usually spared until the most advanced stages of the disease. The AD syndrome evolution reflects the progressive spread of pTAU pathology from the allocortex (entorhinal cortex and hippocampus) to the neocortex (Elahi and Miller, 2017; Hanseeuw et al., 2019). Observing the neuropathology of AD is the starting point for deciphering its pathophysiological mechanisms and, therefore, identifying the biomarkers of the disease and the possible therapeutic targets. The macroscopic pathological feature characterizing advanced AD is diffuse brain atrophy due to widespread neurodegeneration causing synaptic and neuronal loss. Actually, the disease begins decades earlier with amyloid accumulation in the neocortex but amyloid deposition, which is very common even in physiological aging, is not sufficient to cause AD. The fundamental question is: what triggers neurodegeneration? Probably, the excess of amyloid-beta (Aβ) induces neurodegeneration through toxic oligomers. Indeed, soluble Aβ oligomers cause a synaptic reduction with a decrease in long-term potentiation and memory. Moreover, oligomers can reduce blood flow in brain capillaries and induce hyperphosphorylation of the AD-relevant epitopes of TAU protein (Selkoe and Hardy 2016; Nortley et al., 2019). Thus, Aβ load triggers neurodegeneration through oligomers which induce unbalanced activation of neuronal kinases resulting in excessive production of pTAU that, in turn, aggregates in pTAU toxic oligomers and spreads from its initial location in allocortex to neocortex. Together, oligomeric Aβ, synaptic pTAU aggregates and glial inflammatory activation are the main neurotoxic factors involved in the manifestation of a clinically relevant neurocognitive disorder (Perez-Nieves et al., 2013; Jack et al., 2018a). Typically, AD pathology shows extracellular accumulation of Aβ peptides (Aβ or senile plaques), as well as the hyperphosphorylated tau protein aggregates inside the dying neurons named
neurofibrillary tangles (NFT) and neuropil threads (NT). Their combination constitutes the neuritic plaque (NP), which is the most typical feature of AD neuropathology. Thus, the neuropathological definition of AD requires a combination of scores for Amyloid, TAU (Braak stages), and NP (CERAD), which constitute the ABC criteria for the grading of AD related pathology (Mirra et al., 1991; Braak et al., 2006; Montine et al., 2012). Senile and neuritic plaques, consisting of protein and cellular debris, activate reactive and inflammatory processes by astrocytes and microglia which produce cytokines (IL-1β, IL-6) and NLRP3 inflammusome activation that, in turn, increase neurotoxic phenomena (Serrano-Pozo et al., 2016; Ising et al., 2019). On the basis of the neuropathological picture, several biomarkers have been developed for the in vivo definition of the pathology. Thus, the ATN system (Amyloid-TAU-Neurodegeneration) has been set up including 1) estimate of the amyloid load: Aβ decrease in cerebrospinal fluid (CSF) and/or Aβ cortical accumulation at amyloid-PET; 2) pTAU valuation: pTAU increase in CSF and/or pTAU cortical accumulation at TAU-PET; 3) extent of neurodegeneration: atrophic pattern at brain MRI and/or hypometabolism at FDG-PET and/or increase of total-TAU in CSF (Jack et al., 2018b; Chételat et al., 2020). These markers can allow for early diagnosis or even can identify those most at risk of developing AD in a preclinical phase (before mild-NCD) in order to implement timely therapeutic interventions (Dubois et al., 2016). Nonetheless, there is now no cure for AD and this approach poses ethical problems, as well as being invasive and expensive; therefore, an intensive search for biomarkers obtainable from peripheral blood is still in progress (Lewczuk et al., 2018; Molinuevo et al., 2018).

The early mechanisms leading to Aβ accumulation and initial generation of toxic molecules are elusive and multiple, and belong to the individual trajectory of cerebral aging linked to non-modifiable genetic factors (AD-related polymorphisms, APO-E4 allele, and pathogenic mutations in PSN-1-2 and APP genes, and Williamson et al., 2009; Vermunt et al., 2019), and to modifiable factors related to the individual’s personal history including favorable behaviors (regular physical and mental activity, high education, healthy diet, social engagement) and harmful conditions (midlife obesity, diabetes, hypertension, smoke, excessive alcohol, and hearing loss) (Lourida et al., 2019; Livingston et al., 2020). Early pathogenesis of sporadic AD is quite complex. Just as there are different forms of hepatitis that lead to cirrhosis, there are different pathophysiological paths that lead to AD. However, the sine qua non for the development of AD pathophysiology is the accumulation of amyloid in the cerebral cortex. Indeed, many efforts are being made to reduce the presence of amyloid in the cerebral cortex, especially through the use of costly monoclonal antibodies (e.g., phase3 trials: Aducanumab, Gantenerumab; phase2 trial: Crenezumab). Actually, amyloid reduction is only one aspect of the therapeutic approach and there is increasing attention to non-amyloid targets with 121 agents having clinical trials in course for the treatment of AD (Cummings et al., 2020). Particularly, a new challenge is the development of immunotherapies capable of blocking the toxic pTAU species (Bittar et al., 2020). The multifactorial nature of the AD would require an early, long-lasting, and multidimensional therapeutic approach which should be personalized and based on the patient’s clinical and biomarker characteristics (Sperling et al., 2011; Cummings et al., 2018; Hara et al., 2019). The current possible intervention strategies to improve the AD course depend on the stage of pathology and progressively include: prevention measures (healthy and active lifestyle, reduction of detrimental factors), disease modifying treatments (reduction of Aβ load and toxic oligomers, containment of TAU phosphorylation, toxic pTAU species and neuroinflammation, enhancement of neuronal resilience), symptomatic therapies (modulation of synaptic functions and improvement of synaptic efficiency, and Long and Holtzman 2019). Nonetheless, it should be taken into account that many senile cases of AD present mixed pathologies and in the extreme stages of senility it becomes unrealistic to stem neurodegeneration. In this framework, adenosine receptors, especially in the hippocampus, constitute a new and interesting therapeutic target through which it is possible to modulate and improve synaptic activity, obtaining symptomatic and perhaps disease-modifying effects.

ROLE OF A2A ADENOSINE RECEPTORS IN AD: STATE OF THE ART AND DISCUSSION

Adenosine is an ubiquitous autacoid derived by ATP dephosphorylation, that modulates several responses in CNS, by activating four G-protein coupled receptors, A1, A2A, A2B, and A3, present on both neuronal and glial cells (Borea et al., 2018). This nucleoside is generated at both intra- and extracellular level following AMP dephosphorylation by 5′-nucleotidases and its extracellular concentration is regulated both from equilibrative nucleoside transporters as well as through exocytosis by neurons and astrocytes (Borea et al., 2016).

Adenosine regulates several physiological functions including sleep, cognitive performances, and memory and its main role is to regulate neuron excitatory synaptic transmission by inhibitory A1 receptors and synaptic plasticity via facilitatory A2A receptors (Cunha, 2008; Cunha, 2016; Cieślak and Wojtczak, 2018). In particular, the A2A subtype, mainly present in striatal area, has been now recognized in other cerebral regions including cortex and hippocampus, where due to its expression at presynaptic level, it affects the release of excitatory neurotransmitters, like glutamate (Cunha et al., 1994; Lopes et al., 2002; Marchi et al., 2002). As for its synaptic expression in spite of episodic evidence (Canaš et al., 2018), it is still debatable if there is A2A receptors expression in synapses, although it is well established that A2A receptors are located in hippocampal synapses, with a density about 20–time lower than in the striatum (Lopes et al., 2004; Rebola et al., 2005). Although in healthy human brains the A2A receptor may exert protective functions, by regulating other proteins as BDNF, its signaling is strongly modified in the hippocampus following aging (Rebola et al., 2003; Tebano et al., 2010; Temido-Ferreira et al., 2019; Temido-Ferreira et al., 2020). In this condition, there is a rise of A2A receptor
and G proteins-coupling, leading to an increase in glutamate release, mGluR5-dependent NMDA receptor overstimulation, and enhanced calcium influx responsible for synaptic alterations and memory dysfunction (Temido-Ferreira et al., 2020). These findings suggest a role for this receptor subtype in the pathogenesis of different neurocognitive disorders and specifically AD (Costenla et al., 2011; Rebola et al., 2011; Horgusluoglu-Moloch et al., 2017; Temido-Ferreira et al., 2019). Indeed, synaptic dysfunction and damage are key features in early AD (Selkoe, 2002; Coleman et al., 2004). Interestingly, A2A receptor is overexpressed in both frontal cortex and hippocampus of aged and transgenic-AD animals as well as in AD patients (Lopes et al., 1999; Arendash et al., 2006; Albasanz et al., 2008; Espinosa et al., 2013; Li et al., 2015; Orr et al., 2015; Pagnussat et al., 2015; Gonçalves et al., 2019; Temido-Ferreira et al., 2020). APP/PS1 mouse model of AD amyloidosis show an upregulation and activation of A2A adenosine receptors hampering long-term synaptic potentiation (LTP) in hippocampal CA3 pyramidal cells (Viana da Silva et al., 2016). Several literature data report the use of pharmacological and genetic approaches to demonstrate that A2A adenosine receptors block prevents synaptic damage and cognitive impairments in animal models following Aβ exposure, suggesting that A2A receptor antagonists might reduce synaptic ´toxicity (Dall’Igna et al., 2007; Canas et al., 2009; Orr et al., 2018). Moreover, antagonism of A2A adenosine receptors in animal models of Tau pathology inhibits Tau hyperphosphorylation, hippocampal neuroinflammation, while protects spatial memory and hippocampal long-term depression (Laurent et al., 2016). Accordingly, overexpression of A2A adenosine receptors, in a tauopathy mouse model, increases tau hyperphosphorylation and consequent tau-dependent memory impairments (Carvalho et al., 2019).

Adenosine, deriving from an increase of ecto-5'-nucleotidase (CD73) activity in animal model of early AD, induced memory deficits, LTP impairment and synaptic markers reduction in a CD73 or A2A adenosine receptor-dependent way (Gonçalves et al., 2019). Indeed, among the early mechanisms involved in memory deterioration, synaptic dysfunction and selective synaptic degeneration stand out as one of the more robust and reproducible events. In fact, the early works on neuropathological changes associated with dementia established the loss of synaptic markers as a key process (Terry et al., 1991). More recent work showed that the loss of synapses is indeed of the earliest neuropathological changes in the brains of MCI and early AD patients, namely in the hippocampus (Scheff et al., 2007; Scheff et al., 2015). Accordingly, animal studies confirmed that synaptic dysfunction is an early event at the onset of memory perturbations (Canas et al., 2009; Viana da Silva et al., 2016; Silva et al., 2018). This justifies the proposal that AD is a synaptic-based disease (Selkoe, 2002) and that synaptic modulators may be paramount to control early AD (Coleman et al., 2004). Another crucial role for the A2A adenosine receptor is its important ability to modulate glial cell functions, affecting pro-inflammatory cytokines release and neuroinflammation (Illes et al., 2020). Specifically, it plays an essential role in activated microglia, located near amyloid plaques typical of AD (Franco et al., 2020), where its upregulation is responsible for a raise of M1 microglial markers (IL-1β, IL-6, TNF-α) and its antagonism prevents hippocampal LTP impairments, as well as IL-1β production, paving a regulatory function for it in reducing memory dysfunction (Colella et al., 2018; Franco et al., 2019). Several studies support a role of A2A receptor as drug target in both neurons and microglia to revert memory deficit and neurodegeneration in AD (Santiago et al., 2014; Cunha, 2016). Recently, it has been reported that A2A subtypes interact with NMDA receptors producing A2A/NMDA heteromers, mainly in microglia, characterized by bidirectional cross-antagonism, where A2A receptor inhibition decreases hyperactivation of glutamatergic signalling by blocking NMDA receptor-mediated currents (Rebola et al., 2008; Mouro et al., 2018; Franco et al., 2020; Temido-Ferreira et al., 2020). In addition, it forms important complexes with CB2 cannabinoid receptor subtypes, presenting cross-interaction, thus modifying the pathway of each other. In this heteromer, A2A receptor antagonism provides an increase in CB2 receptor activity suggesting, for the first time, that A2A receptor block rises the neuroprotective action of endocannabinoids important for AD therapy (Franco et al., 2019). Interestingly, these receptorial complexes were enhanced in a transgenic AD mouse model (Franco et al., 2020). Although these heteromers might have a role, recently, A2A receptor-mediated effects in AD-related features have been attributed to monomeric forms (Temido-Ferreira et al., 2020).

Clinical data, based on the effect of caffeine consumption in elderly, encourage the use of A2A adenosine antagonists to prevent memory deficits. Indeed, caffeine is the most widely consumed psychostimulant substance, present in coffee, tea, cola, chocolate, and other foods, exerting beneficial effects in dementia and AD (Eskelinen et al., 2009; Eskelinen and Kivipelto, 2010; Santos et al., 2010; Gelber et al., 2011; Liu et al., 2016; Sugiyama et al., 2016; Reyes and Cornelis, 2018; Domenici et al., 2019; Dong et al., 2020; Iranpour et al., 2020). Interestingly it has been reported that non-toxic doses/ concentrations of caffeine mostly act on A2A receptors in the brain (Yu et al., 2009; Lopes et al., 2019). Accordingly, antagonism of A2A receptors is one of the main effects of caffeine (Jacobson et al., 2020).

Specifically, coffee consumption correlated with reduction of cognitive function, with significant effects obtained with three cups of coffee per day (Ritchie et al., 2007; van Gelder et al., 2007). Indeed, a retrospective analysis during 20 years before AD development, revealed a negative correlation between coffee intake and disease diagnosis, with lower quantity of caffeine at day assumed by patients with AD in contrast to higher amounts of caffeine in control subjects (Maia and de Mendonca, 2002). Furthermore, a prospective work evaluating the effect of coffee intake assumed every day on AD development, showed a reduction of AD risk by 31%, following 5 years examination (Lindsay et al., 2002). In addition, lower caffeine levels were observed in plasma of mild cognitive impairments patients developing later dementia, in comparison to those who did not develop the disease. Therefore, high levels of caffeine were related to the lack of dementia development in a window of 2/4 years (Cao et al., 2012). Accordingly, a high daily consumption...
of 3–5 cups of coffee reduced the risk of dementia and AD of 65–70 and 62–64%, respectively, in comparison to a lower assumption (Eskelinen et al., 2009). More generally, caffeine intake was associated to the absence of dementia and cerebral injuries typical of AD and to an increase of long-term memories consolidation in humans (Gelber et al., 2011; Borota et al., 2014; Favila and Kuhl, 2014).

In animal models of AD, administration of caffeine, has been associated to a reduced risk for memory decline and dysfunction, beta-amyloid production and tau hyperphosphorylation (Costa et al., 2008; Arendash et al., 2009; Canas et al., 2009; Cao et al., 2009; Eskelinen and Kivipelto, 2010; Santos et al., 2010; Laurent et al., 2014; Kaster et al., 2015; Kolahdouzan and Hamadeh, 2017). Finally, recent works support the utility of caffeine intake as antioxidant and antiinflammatory agent (Janitschke et al., 2019; Sinyor et al., 2020). However, it has to be remarked that although caffeine is an abundant bioactive molecule in coffee beverages, these have over 2,000 other chemicals that may have biological effects. In this respect, it is interesting that it is the amounts of a caffeine metabolite, the obromine, rather than caffeine levels in the CSF that correlate with amyloid/tau markers in demented patients (Travassos et al., 2015). Interestingly, the intake of chocolate, rich in the obromine, is inversely correlated with memory deterioration (Moreira et al., 2016).

It is important to remark that the neuroprotective effects of caffeine, associated to A2A adenosine receptor inhibition, have been observed also in Parkinson’s disease, where much work has been carried out to demonstrate safety of the first A2A adenosine receptor antagonist, istradefylline, recently launched as a new drug for this pathology in Japan (Nouriast) and in the United States (Nouriast) (Borea et al., 2016, Borea et al., 2017; Chen and Cunha, 2020). Istradefylline has been also shown to exert protective effects by reducing memory dysfunction in animal models of AD and for the future it would be crucial to determine whether it could also induce memory improvement in patients with AD (Orr et al., 2018). However, it should be underlined that istradefylline has a narrow therapeutic window in aging and experimental models of AD and PD, leading to the hypothesis that age and other factors may affect safety of A2A receptor antagonists.

Finally, this opinion article has presented the main findings supporting the role of A2A adenosine receptor antagonists on AD. Even though further work is necessary to better elucidate the mechanisms involved in the shift of A2A receptor from beneficial target in normal synapses to detrimental one in aging and disease, its capability to modulate synaptotoxicity, glutamate-dependent NMDA signaling and calcium dysfunction, together with its effect on neuroinflammation, suggest a crucial role for its antagonism to prevent AD pathology.

**AUTHOR CONTRIBUTIONS**

SM, SG, PAB, and TEP conceived the work and wrote the manuscript. LP, SP, FV, and KV contributed to writing and editing. All authors contributed to the article and approved the submitted version.

**REFERENCES**

Albasanz, J. L., Perez, S., Barrachina, M., Ferrer, I., and Martin, M. (2008). Up-regulation of adenosine receptors in the frontal cortex in Alzheimer’s disease. *Brain Pathol.* 18, 211–219. doi:10.1111/j.1750-3639.2007.00112.x

American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (DSM-5). 5th Edn. American Psychiatric Publishing, Inc. Available at: https://books.google.it/books?id=JvBAAAQBAJ (Accessed May 18, 2013).

Arendash, G. W., Mori, T., Cao, C., Mamacz, M., Runfeldt, M., Dickson, A., et al. (2009). Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer’s disease mice. *J. Alzheimers Dis.* 17, 661–680. doi:10.3233/JAD-2009-1087

Arendash, G. W., Schleif, W., Rezai-Zadeh, K., Jackson, E. K., Zacharia, L. C., Cracchiolo, J. R., et al. (2006). Caffeine protects Alzheimer’s mouse against cognitive impairment and reduces brain beta-amyloid production. *Neuroscience* 142, 941–952. doi:10.1016/j.neuroscience.2006.07.021

Bittar, A., Bhatt, N., and Kayed, R. (2020). Advances and considerations in AD tau-targeted immunotherapy. *Neurobiol. Dis.* 134, 104707. doi:10.1016/j.nbd.2019.104707

Borea, P. A., Gessi, S., Merighi, S., and Varani, K. (2016). Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects? *Trends Pharmacol. Sci.* 37, 419–434. doi:10.1016/j.tips.2016.02.006

Borea, P. A., Gessi, S., Merighi, S., Vincenzii, F., and Varani, K. (2017). Pathological overproduction: the bad side of adenosine. *Br. J. Pharmacol.* 174, 1945–1960. doi:10.1111/bph.13763

Borea, P. A., Gessi, S., Merighi, S., Vincenzii, F., and Varani, K. (2018). Pharmacology of adenosine receptors: the state of the art. *Physiol. Rev.* 98, 1591–1625. doi:10.1152/physrev.00049.2017

Borota, D., Murray, E., Kecchi, G., Chang, A., Watabe, J. M., Ly, M., et al. (2014). Post-study caffeine administration enhances memory consolidation in humans. *Nat. Neurosci.* 17, 201–203. doi:10.1038/nn.3623

Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., and Del Tredici, K. (2006). Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol.* 112, 389–404. doi:10.1007/s00401-006-0127-z

Canas, P. M., Porciúncula, L. O., Cunha, G. M., Silva, C. G., Machado, N. J., Oliveira, J. M., et al. (2009). Adenosine A3A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. *J. Neurosci.* 29, 14741–14751. doi:10.1523/JNEUROSCI.3728-09.2009

Canas, P. M., Porciúncula, L. O., Simões, A. P., Augusto, E., Silva, H. B., Machado, N. J., et al. (2018). Neuronal adenosine A3A receptors are critical mediators of neurodegeneration triggered by convulsions. *eNeuro* 5 (6), 0385–418. doi:10.1523/ENEURO.0385-18.2018

Cao, C., Cirrito, J. R., Liu, X., Wang, L., Wang, L., Verges, D. K., et al. (2009). Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer’s disease transgenic mice. *J. Alzheimers Dis.* 17, 681–697. doi:10.3233/JAD-2009-1071

Cao, C., Loewenstein, D. A., Lin, X., Zhang, C., Wang, L., Duara, R., et al. (2012). High Blood caffeine levels in MCI linked to lack of progression to dementia. *J. Alzheimer’s Dis.* 30, 559–572. doi:10.3233/JAD-2012-111781

Carvalho, K., Faivre, E., Pietrowski, M. J., Marques, X., Gomez-Murcia, V., Deleau, A., et al. (2019). Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A3A receptor. *Brain* 142, 3636–3654. doi:10.1093/brain/awz288

Chen, J. F., and Cunha, R. A. (2020). The belated United States FDA approval of the adenosine A3A receptor antagonist istradefylline for treatment of Parkinson’s disease. *Purinergic Signal.* 16, 167–174. doi:10.1007/s11302-020-09694-2

Merighi et al. A**2A** Adenosine Receptors in AD
Silva, A. C., Lemos, C., Gonçalves, F. Q., Plásssova, A. V., Machado, N. J., Silva, H. B., et al. (2018). Blockade of adenosine A2A receptors recovers early deficits of memory and plasticity in the triple transgenic mouse model of Alzheimer’s disease. *Neurobiol. Dis.* 117, 72–81. doi:10.1016/j.nbd.2018.05.024

Sinyor, B., Mineo, J., and Ochner, C. (2020). Alzheimer’s disease, inflammation, and the role of antioxidants. *J. Alzheimers. Dis. Rep.* 4, 175–183. doi:10.3233/ADR-200171

Sperling, R. A., Jack, C. R., Jr, and Aisen, P. S. (2011). Testing the right target and right drug at the right stage. *Sci. Transl. Med.* 3, 111cm33. doi:10.1126/scitranslmed.3002609

Sugiyama, K., Tomata, Y., Kaiho, Y., Honkura, K., Sugawara, Y., and Tsuji, I. (2016). Association between coffee consumption and incident risk of disabling dementia in elderly Japanese: the ohsaki cohort 2006 study. *J. Alzheimers. Dis.* 50, 491–500. doi:10.3233/JAD-150693

Tebanó, M. T., Martire, A., Chiodi, V., Ferrante, A., and Popoli, P. (2010). Role of adenosine A2A receptors in modulating synaptic functions and brain levels of BDNF: a possible key mechanism in the pathophysiology of Huntington’s disease. *Sci. World J.* 10, 1768–1782. doi:10.1100/tsw.2010.164

Temido-Ferreira, M., Coelho, J. E., Pousinha, P. A., and Lopes, L. V. (2019). Novel players in the aging synapse: impact on cognition. *J. Caffeine Adenosine Res.* 9, 104–127. doi:10.1089/caff.2019.0013

Temido-Ferreira, M., Ferreira, D. G., Batalha, V. L., Marques-Morgado, I., Coelho, J. E., Pereira, P., et al. (2020). Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors. *Mol. Psychiatry* 25, 1876–1900. doi:10.1038/s41380-018-0110-9

Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., et al. (1991). Physical basis of cognitive alterations in Alzheimer’s disease: synaptic loss is the major correlate of cognitive impairment. *Ann. Neurol.* 30, 572–580. doi:10.1002/ana.410300410

Travassos, M., Santana, I., Baldeiras, I., Tsolakí, M., Gkatzioma, O., Sermin, G., et al. (2015). Does caffeine consumption modify cerebrospinal fluid amyloid β levels in patients with alzheimer’s disease?. *J. Alzheimers Dis.* 47, 1069–1078. doi:10.3233/JAD-150374

van Gelder, B. M., Buijsse, B., Tijhuis, M., Kalmijn, S., Giampaoli, S., Nissinen, A., et al. (2007). Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. *Eur. J. Clin. Nutr.* 61, 226–232. doi:10.1038/sj.ejcn.1602495

Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., et al. (2019). Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. *Alzheimers Dement.* 15, 888–898. doi:10.1016/j.jalz.2019.04.001

Viana da Silva, S., Haberl, M. G., Zhang, P., Bethge, P., Lemos, C., Gonçalves, N., et al. (2016). Early synaptic deficits in the APP/PS1 mouse model of Alzheimer’s disease involve neuronal adenosine A2A receptors. *Nat. Commun.* 7, 11915. doi:10.1038/ncomms11915

Williamson, J., Goldman, J., and Marder, K. S. (2009). Genetic aspects of Alzheimer disease. *Neurologist* 15, 80–86. doi:10.1097/NRL.0b013e318187e76b

Yu, L., Coelho, J. E., Zhang, X., Fu, Y., Tillman, A., Karaouz, U., et al. (2009). Uncovering multiple molecular targets for caffeine using a drug target validation strategy combining A2A receptor knockout mice with microarray profiling. *Physiol. Genomics.* 37, 199–210. doi:10.1152/physiolgenomics.90353.2008

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Merighi, Poloni, Pelloni, Pasquini, Varani, Vincenzi, Borea and Gessi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.